Only 24 percent of dialysis patients achieve their phosphate targets
For the roughly 95 percent of dialysis patients worldwide whose bodies cannot shed excess phosphorus, the gap between medical need and effective treatment has long been measured in cardiovascular events and shortened lives. In May 2026, Shanghai-based Alebund Pharmaceuticals completed enrollment in RESPOND-2, a global Phase III trial testing AP301 — a fiber-iron phosphate binder designed to outperform existing therapies in tolerability and adherence — across sites in the United States and China. With the FDA already recognizing this single trial as sufficient pivotal evidence for U.S. approval, and Chinese regulatory submission on the horizon, the drug's journey reflects a broader reckoning with how medicine serves patients whose conditions are common yet chronically undertreated.
- Nearly all dialysis patients carry dangerously elevated phosphate levels, yet fewer than half in the U.S. — and only one in four in China — actually reach safe targets under current treatments.
- Existing phosphate binders demand patients swallow handfuls of pills daily while enduring gastrointestinal side effects, creating a compliance crisis with life-or-death consequences including vascular calcification and heart disease.
- AP301's fiber-iron design promises stronger binding capacity, better tolerability, and a lower pill burden — directly targeting the reasons patients abandon treatment in the first place.
- Earlier China-only data from RESPOND-1 showed AP301 matched and then surpassed sevelamer carbonate over 52 weeks, with two-thirds of patients hitting phosphate targets at a lower daily dose.
- Enrollment in the global RESPOND-2 trial has now closed at 282 patients — exceeding its own target — with the FDA's blessing that this single study can unlock U.S. approval, compressing the typical regulatory timeline.
In May 2026, Alebund Pharmaceuticals announced the completion of enrollment for RESPOND-2, its global Phase III trial of AP301, a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. The trial enrolled 282 participants across the United States and China — slightly more than the 264 originally planned — and carries unusual regulatory weight: the FDA has already agreed it will serve as the single pivotal study needed to support U.S. approval.
Hyperphosphatemia is a condition that shadows nearly every dialysis patient. Because dialysis cannot fully clear the phosphorus that accumulates in the body, and dietary restriction offers only limited relief, roughly 95 percent of dialysis patients worldwide live with chronically elevated phosphate levels. The downstream consequences — vascular calcification, bone disease, secondary hyperparathyroidism, and elevated cardiovascular mortality — are severe. Yet current phosphate binders fail patients in practice: gastrointestinal side effects, high daily pill counts, and tolerability problems drive poor adherence, leaving target phosphate levels out of reach for the majority of patients in every major market studied.
AP301 was designed to close that gap. As a fiber-iron-based binder, it offers higher binding capacity without requiring patients to chew tablets, with minimal systemic iron absorption and better gastrointestinal tolerability. The RESPOND-2 trial tests these properties through a structured sequence: a double-blind dose titration phase, followed by open-label treatment, and a withdrawal phase to confirm lasting effect.
Alebund already has a body of evidence behind it. The earlier China-based RESPOND-1 trial, which enrolled 474 patients across 50 sites, demonstrated that AP301 was non-inferior to sevelamer carbonate at 12 weeks and pulled ahead by week 52 — achieving a 66.7 percent target attainment rate versus 58.6 percent for sevelamer, at a meaningfully lower daily dose. Side effects were largely limited to discolored feces and transient mild diarrhea in early weeks, and no iron accumulation signals emerged across the full year of treatment.
With enrollment complete and regulatory alignment secured in both the U.S. and China, Alebund is moving toward submission in both markets. The global phosphorus-lowering drug market is projected to reach six billion dollars by 2035, and the company — founded in Shanghai in 2018 — has already built manufacturing infrastructure and a commercialization team in anticipation of that opportunity.
Alebund Pharmaceuticals announced in May 2026 that it had finished enrolling patients in a global Phase III trial for AP301, a new type of phosphate binder designed to treat hyperphosphatemia—a condition where the body retains too much phosphorus. The trial, called RESPOND-2, enrolled 282 patients with chronic kidney disease on maintenance dialysis across the United States and China, exceeding the originally planned 264 participants. This enrollment milestone matters because the FDA has already agreed that this single global trial will serve as the pivotal evidence needed to support approval of AP301 in the United States, streamlining what is typically a longer regulatory path.
Hyperphosphatemia is far more common than most people realize. It affects roughly 95 percent of dialysis patients worldwide and about 15 percent of those with chronic kidney disease who are not yet on dialysis. The condition develops because regular dialysis alone cannot remove all the excess phosphorus that accumulates in the body, and dietary restriction has limited effectiveness. When phosphate levels stay chronically elevated, the consequences are serious: vascular calcification, secondary hyperparathyroidism, bone disease, and increased risk of cardiovascular events and death. Despite the stakes, current treatments fall short. Existing phosphate binders cause gastrointestinal side effects, require patients to swallow many pills daily, and sometimes carry risks of systemic absorption. The result is poor adherence. According to data from the Dialysis Outcomes and Practice Patterns Study, only about 24 percent of dialysis patients in China, 48 percent in the United States, and 61 percent in Japan actually achieve target phosphate levels. In China specifically, the target attainment rate sits at just 40 percent.
AP301 is designed to address these shortcomings. As a fiber-iron-based phosphate binder, it promises higher phosphate-binding capacity, better gastrointestinal tolerability, minimal risk of iron accumulation in the body, and no need to chew before swallowing—features intended to improve how well patients stick with treatment. The RESPOND-2 trial structure reflects careful design: an eight-week double-blind dose titration phase comparing AP301 to an ineffective low dose, followed by 24 weeks of open-label treatment, then a three-week randomized withdrawal phase to confirm durability. The primary endpoint measures change in serum phosphate from baseline through the titration phase.
Alebund already has encouraging data from an earlier Phase III trial conducted in China. That study, called RESPOND-1, enrolled 474 patients across 50 sites and showed that AP301 was non-inferior to sevelamer carbonate, a widely used phosphate binder. At week 12, AP301 reduced serum phosphate by 2.22 mg/dL compared to 2.17 mg/dL for sevelamer, meeting the pre-specified non-inferiority threshold. By week 27, patients on the AP301 maintenance dose showed significantly better phosphate control than those on the ineffective low dose. At 52 weeks, AP301 achieved a higher target attainment rate—66.7 percent versus 58.6 percent—while requiring a lower daily dose: 6.52 grams per day versus 7.56 grams. The most common side effects were discolored feces and diarrhea, with diarrhea typically mild, appearing in the first two to four weeks, and rarely leading to treatment discontinuation. Critically, no safety signals related to iron accumulation emerged over the full 52-week treatment period.
The commercial opportunity is substantial. The global market for phosphorus-lowering drugs is projected to reach six billion dollars by 2035, with China alone expected to account for ten billion yuan. Alebund, founded in Shanghai in 2018, has already built manufacturing capacity in Yangzhou and assembled a commercialization team in China. The company has obtained regulatory alignment with China's NMPA and plans to submit a New Drug Application in the near future. With enrollment now complete and FDA agreement that RESPOND-2 serves as the pivotal trial for U.S. approval, AP301 is positioned to move toward regulatory decisions in both markets within the next phase of development.
Notable Quotes
The on-time completion of patient enrollment reflects Alebund's ability to advance high-quality global clinical development, which is an important milestone in the global registrational development of AP301.— Jin Tian, M.D., Co-founder and Chief Medical Officer of Alebund Pharmaceuticals
The Hearth Conversation Another angle on the story
Why does it matter that this trial enrolled 282 patients instead of the planned 264? Isn't that just a rounding difference?
It shows the trial actually worked as designed—they didn't struggle to find patients. In rare disease trials, enrollment can drag for years. Completing on time and slightly over target signals the drug addresses a real, felt need among patients and physicians.
The source mentions that only 40 percent of Chinese dialysis patients hit their phosphate targets. That's a staggering failure rate. Why is adherence so bad?
Current binders cause diarrhea and bloating, require swallowing six or seven pills daily, and some carry the risk of iron buildup over time. Imagine managing a chronic condition while dealing with constant GI distress and a pill burden that disrupts your day. Most people stop taking them.
AP301 requires no chewing. That seems like a small detail. Why is it in the marketing?
It's not marketing—it's a real barrier removed. Elderly patients with arthritis, patients with swallowing difficulties, people on multiple medications already—these details compound. Removing one friction point can be the difference between someone taking the drug consistently or abandoning it.
The trial showed diarrhea in the first two to four weeks, then it resolved. How do we know patients won't just quit before it gets better?
That's the real-world question the RESPOND-2 trial will help answer. The earlier China trial showed only 0.6 percent of patients discontinued due to diarrhea, which is remarkably low. But that's in a controlled trial setting where patients are monitored. The global trial will test whether that holds across different healthcare systems and patient populations.
What happens if AP301 gets approved? Does it immediately replace sevelamer?
Not necessarily. Sevelamer is established, familiar, and covered by insurance. AP301 will likely be positioned as an option for patients who struggle with current binders—those with GI side effects, those who can't manage the pill burden, or those not hitting their targets. It's a better tool for a subset of patients, not a universal replacement.